BostonGene and Prisma Health Collaborate on Predicting Immunotherapy Efficacy in Rare Cancers

Friday, January 19, 2024

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, has announced a strategic collaboration with Prisma Health to advance research on rare tumors. The collaboration focuses on the comprehensive characterization of the tumor microenvironment (TME), mutational landscape, and host immune profiles in patients undergoing treatment with immune checkpoint inhibitors.

Working in conjunction with Prisma Health's Rare Tumor Center, BostonGene will analyze tissue and peripheral blood samples from patients with rare solid tumors. The primary objective is to deepen the understanding of the molecular mechanisms underlying immune-activating drugs designed to boost the body's inherent ability to combat cancer.

As part of the ongoing clinical trial, BostonGene will conduct thorough analyses on primary tumors and immunoprofiling of corresponding peripheral blood samples. The trial is actively enrolling patients, with the goal of expanding insights into the interplay between cancer and surrounding tissue, as well as normal supportive cells.

BostonGene's innovative solutions are expected to provide a more comprehensive understanding of the molecular profiles of patients with rare tumors. This, in turn, could contribute to the identification of tailored and effective therapies for individual patients. BostonGene's computational platform seamlessly integrates genomic, transcriptomic, and immunoprofiling data to evaluate the TME and host immune status, elucidating somatic alterations, gene expression, fusions, tumor heterogeneity, and immunoprofiles.


Harvard Medical School - Leadership in Medicine Southeast Asia47th IHF World Hospital CongressHealthcare Innovation & Transformation SummitHealthcare CNO SummitHealthcare CMO SummitThe Healthcare Patient Experience & Engagement Summit 2024